Interleukin-6 Inhibitor Olokizumab in Hospitalized Adults with Moderate COVID-19: Results of a Single Center Observational Study
A single-center observational study was performed to evaluate the effectiveness and safety of the interleukin-6 inhibitor olokizumab in hospitalized adults with moderate COVID-19. This study enrolled 337 patients aged from 22 to 96 years old. After the administration of olokizumab, there was a sign...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Knowledge E
2024-12-01
|
| Series: | West Kazakhstan Medical Journal |
| Subjects: | |
| Online Access: | https://knepublishing.com/index.php/wkmj/article/view/17780 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846114405439242240 |
|---|---|
| author | Svetlana V Topolyanskaya Rachina S.A. Karine A. Lytkina Georgiy G. Melkonyan Yulia A Savochkina |
| author_facet | Svetlana V Topolyanskaya Rachina S.A. Karine A. Lytkina Georgiy G. Melkonyan Yulia A Savochkina |
| author_sort | Svetlana V Topolyanskaya |
| collection | DOAJ |
| description |
A single-center observational study was performed to evaluate the effectiveness and safety of the interleukin-6 inhibitor olokizumab in hospitalized adults with moderate COVID-19. This study enrolled 337 patients aged from 22 to 96 years old. After the administration of olokizumab, there was a significant reduction in body temperature, decrease in CRP, and an increase in the levels of blood cells. Revealed clinical improvement was seen in 69.7% of cases, 8.5% of patients showed deterioration in their condition and were transferred to the ICU, 13.6% died. Olokizumab was well tolerated except for slight elevation in live enzymes, such as aspartate transaminase and alanine transaminase.
|
| format | Article |
| id | doaj-art-d96b0b2149264879a7fa2434ed78d4a1 |
| institution | Kabale University |
| issn | 2707-6180 2707-6199 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Knowledge E |
| record_format | Article |
| series | West Kazakhstan Medical Journal |
| spelling | doaj-art-d96b0b2149264879a7fa2434ed78d4a12024-12-20T12:51:19ZengKnowledge EWest Kazakhstan Medical Journal2707-61802707-61992024-12-0166410.18502/wkmj.v66i4.17780Interleukin-6 Inhibitor Olokizumab in Hospitalized Adults with Moderate COVID-19: Results of a Single Center Observational StudySvetlana V Topolyanskaya0Rachina S.A.1Karine A. Lytkina2Georgiy G. Melkonyan3Yulia A Savochkina4Department of Internal Medicine #2, First Moscow State Medical University (Sechenov University), MoscowDepartment of Internal Medicine #2, First Moscow State Medical University (Sechenov University), MoscowWar Veterans Hospital #3, MoscowWar Veterans Hospital #3, MoscowFederal State Budgetary Institution, Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, Moscow A single-center observational study was performed to evaluate the effectiveness and safety of the interleukin-6 inhibitor olokizumab in hospitalized adults with moderate COVID-19. This study enrolled 337 patients aged from 22 to 96 years old. After the administration of olokizumab, there was a significant reduction in body temperature, decrease in CRP, and an increase in the levels of blood cells. Revealed clinical improvement was seen in 69.7% of cases, 8.5% of patients showed deterioration in their condition and were transferred to the ICU, 13.6% died. Olokizumab was well tolerated except for slight elevation in live enzymes, such as aspartate transaminase and alanine transaminase. https://knepublishing.com/index.php/wkmj/article/view/17780COVID-19C-reactive proteininterleukin-6olokizumab How |
| spellingShingle | Svetlana V Topolyanskaya Rachina S.A. Karine A. Lytkina Georgiy G. Melkonyan Yulia A Savochkina Interleukin-6 Inhibitor Olokizumab in Hospitalized Adults with Moderate COVID-19: Results of a Single Center Observational Study West Kazakhstan Medical Journal COVID-19 C-reactive protein interleukin-6 olokizumab How |
| title | Interleukin-6 Inhibitor Olokizumab in Hospitalized Adults with Moderate COVID-19: Results of a Single Center Observational Study |
| title_full | Interleukin-6 Inhibitor Olokizumab in Hospitalized Adults with Moderate COVID-19: Results of a Single Center Observational Study |
| title_fullStr | Interleukin-6 Inhibitor Olokizumab in Hospitalized Adults with Moderate COVID-19: Results of a Single Center Observational Study |
| title_full_unstemmed | Interleukin-6 Inhibitor Olokizumab in Hospitalized Adults with Moderate COVID-19: Results of a Single Center Observational Study |
| title_short | Interleukin-6 Inhibitor Olokizumab in Hospitalized Adults with Moderate COVID-19: Results of a Single Center Observational Study |
| title_sort | interleukin 6 inhibitor olokizumab in hospitalized adults with moderate covid 19 results of a single center observational study |
| topic | COVID-19 C-reactive protein interleukin-6 olokizumab How |
| url | https://knepublishing.com/index.php/wkmj/article/view/17780 |
| work_keys_str_mv | AT svetlanavtopolyanskaya interleukin6inhibitorolokizumabinhospitalizedadultswithmoderatecovid19resultsofasinglecenterobservationalstudy AT rachinasa interleukin6inhibitorolokizumabinhospitalizedadultswithmoderatecovid19resultsofasinglecenterobservationalstudy AT karinealytkina interleukin6inhibitorolokizumabinhospitalizedadultswithmoderatecovid19resultsofasinglecenterobservationalstudy AT georgiygmelkonyan interleukin6inhibitorolokizumabinhospitalizedadultswithmoderatecovid19resultsofasinglecenterobservationalstudy AT yuliaasavochkina interleukin6inhibitorolokizumabinhospitalizedadultswithmoderatecovid19resultsofasinglecenterobservationalstudy |